Trial Profile

The Impact of Velcade [bortezomib] on Antibody Secreting Cells in Sensitized Renal Allograft Candidates.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary)
Indications Renal transplant rejection
Focus Therapeutic Use
Sponsors Takeda Oncology

Most Recent Events

01 Jul 2016 Results published in the Transplantation
28 Apr 2016 Treatment arms changed from 1 to 3 with 4, 16 and 32 dose groups.
28 Apr 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com